RAD Achieves Partial Response in Phase 1 Trial of RAD204
Open PDF
| Stock | Radiopharm Theranostics Ltd (RAD.ASX) |
|---|---|
| Release Time | 22 Jul 2026, 8:32 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
RAD Achieves Partial Response in Phase 1 Trial of RAD204
Key Points
- First RECIST-confirmed durable Partial Response at highest dose level
- Second patient shows early tumor shrinkage and remains progression-free
- RAD204 well-tolerated with no dose-limiting toxicities observed
- Positive initial data supports the therapeutic potential of RAD204
Full Summary
Radiopharm Theranostics announced updated results from the ongoing Phase 1 trial of RAD204, its PD-L1-targeted lutetium-177 nanobody radiotherapeutic, in patients with advanced solid tumors post-immunotherapy. The trial's third cohort, at the highest dose level of 90 mCi, achieved a confirmed durable partial response in the first patient, with a 43% reduction in target lesions. The patient remains progression-free beyond seven months. The second patient showed early tumor shrinkage and is also progression-free. RAD204 has demonstrated a favorable safety profile with no dose-limiting toxicities observed. These results support the therapeutic potential of RAD204 in PD-L1-associated malignancies.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In